Becton, Dickinson and Company (NYSE:BDX) Shares Bought by EagleClaw Capital Managment LLC

EagleClaw Capital Managment LLC increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 264.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 25,795 shares of the medical instruments supplier’s stock after buying an additional 18,721 shares during the quarter. EagleClaw Capital Managment LLC’s holdings in Becton, Dickinson and Company were worth $6,219,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Axxcess Wealth Management LLC grew its holdings in Becton, Dickinson and Company by 30.2% during the 1st quarter. Axxcess Wealth Management LLC now owns 11,051 shares of the medical instruments supplier’s stock valued at $2,735,000 after purchasing an additional 2,565 shares in the last quarter. Cetera Investment Advisers lifted its stake in shares of Becton, Dickinson and Company by 380.8% in the first quarter. Cetera Investment Advisers now owns 58,923 shares of the medical instruments supplier’s stock worth $14,580,000 after acquiring an additional 46,668 shares in the last quarter. Canada Pension Plan Investment Board lifted its stake in shares of Becton, Dickinson and Company by 15.6% in the first quarter. Canada Pension Plan Investment Board now owns 280,193 shares of the medical instruments supplier’s stock worth $69,334,000 after acquiring an additional 37,851 shares in the last quarter. M&G Plc boosted its holdings in Becton, Dickinson and Company by 0.9% in the second quarter. M&G Plc now owns 709,259 shares of the medical instruments supplier’s stock valued at $165,967,000 after purchasing an additional 6,052 shares during the last quarter. Finally, Benson Investment Management Company Inc. grew its stake in Becton, Dickinson and Company by 13.2% during the 3rd quarter. Benson Investment Management Company Inc. now owns 22,315 shares of the medical instruments supplier’s stock valued at $5,380,000 after purchasing an additional 2,602 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on BDX shares. Raymond James reduced their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Stifel Nicolaus increased their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Evercore ISI boosted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock traded down $0.93 during midday trading on Wednesday, reaching $221.71. 49,925 shares of the stock traded hands, compared to its average volume of 1,403,702. The firm has a fifty day moving average price of $235.78 and a two-hundred day moving average price of $234.80. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $249.89. The firm has a market cap of $64.08 billion, a price-to-earnings ratio of 37.50, a PEG ratio of 1.68 and a beta of 0.43. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period in the prior year, the company posted $3.42 EPS. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be issued a $1.04 dividend. The ex-dividend date is Monday, December 9th. This represents a $4.16 annualized dividend and a yield of 1.88%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio is presently 63.97%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.